Dylan Wint, MD
Psychiatry · Las Vegas, NVNPI 1922057116
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Biogen at 50.4% of the total. Reporting peaked in 2020 at $21,996 and has fallen 52.5% since, to $10,459 in 2025. Among psychiatry clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 94 payments — averaging $909.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$43K
- Lilly USA, LLC$19K
- Acadia Pharmaceuticals Inc$14K
- Eli Lilly$8K
- Eisai Inc.$1K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$270
- plus $255 from 2 others
Across 15 payments — averaging $12,455 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$74K
- Genentech, Inc.$65K
- Biogen$48K
What the payments were for
- Consulting fees$43,40151%
- Speaking & faculty fees$37,46944%
- Travel & lodging$3,1594%
- Food & beverage$1,4742%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 31 | $43,052 |
| Lilly USA, LLC | 34 | $18,697 |
| Acadia Pharmaceuticals Inc | 13 | $13,896 |
| Eli Lilly | 8 | $7,931 |
| Eisai Inc. | 2 | $1,402 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $270 |
| Otsuka America Pharmaceutical, Inc. | 2 | $214 |
| GE HealthCare | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$85,503 in reported general payments places this provider in the 95th percentile of 243 psychiatry providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 30 | $238,718 |
| LeqembiLecanemab-Irmb | 20 | $34,644 |
| Rivastigmine | 44 | $8,790 |
| Galantamine ErGalantamine Hbr | 42 | $5,920 |
| Memantine Hcl ErMemantine Hcl | 27 | $4,806 |
| Donepezil Hcl | 284 | $2,689 |
| Memantine Hcl | 77 | $2,425 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 35 | $1,351 |
| Aripiprazole | 40 | $1,072 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 37 | $1,072 |
| Escitalopram Oxalate | 74 | $1,069 |
| Duloxetine Hcl | 40 | $771 |
| Clonazepam | 27 | $678 |
| Bupropion XlBupropion Hcl | 26 | $610 |
| Buspirone Hcl | 24 | $579 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $13,896 | $238,71830 claims |
| Eisai Inc.Leqembi | $1,402 | $34,64420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 243 psychiatry providers in Nevada.
Other psychiatry in Las Vegas
- Jelena KunovacLas Vegas$1.2M
- John AnooshianLas Vegas$836K
- Sam ZandLas Vegas$410K
- Aaron RitterLas Vegas$173K
- Mustafa RawafLas Vegas$166K
- Mujeeb ShadLas Vegas$55K
- Dax WolfordLas Vegas$29K
- Faisal SubaLas Vegas$15K
- Ejine OkoroaforLas Vegas$13K
- John VallesLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.